Allogene Therapeutics (ALLO) Options Chain & Prices $1.44 -0.06 (-3.67%) As of 10:31 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest ALLO Put and Call Options List 5/21/2027 2/19/2027 11/20/2026 10/16/2026 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max More filters Fewer filters Done 0 Results Export ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades10/16/2026$1.50$0.075Call20 - 2010(+0)79.00% (+6.13%)0.5031371End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies BioCryst Pharmaceuticals Options Aurinia Pharmaceuticals Options ADMA Biologics Options Vericel Options Kodiak Sciences Options Nuvation Bio Options Recursion Pharmaceuticals Options Sarepta Therapeutics Options Mesoblast Options Biohaven Options Options Chain Tools Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:ALLO) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
